AbbVie's Skyrizi nabs psoriatic arthritis nod, its second, shortly after Rinvoq | FiercePharma

Retrieved on: 2022-01-24 17:57:34

Tags for this article:

Click the tags to see associated articles and topics

AbbVie's Skyrizi nabs psoriatic arthritis nod, its second, shortly after Rinvoq | FiercePharma. View article details on hiswai:

Excerpt

Last year, BMO Capital Markets analyst Gary Nachman forecast $350 million in psoriatic arthritis sales for the drug by 2025.

Article found on: www.fiercepharma.com